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Abstract
Exposure to ionizing radiation was shown to result in an increased risk of breast cancer. There is strong evidence that steroid
hormones influence radiosensitivity and breast cancer risk. Tumors may be initiated by a small subpopulation of cancer
stem cells (CSCs). In order to assess whether the modulation of radiation-induced breast cancer risk by steroid hormones
could involve CSCs, we measured by flow cytometry the proportion of CSCs in irradiated breast cancer cell lines after
progesterone and estrogen treatment. Progesterone stimulated the expansion of the CSC compartment both in
progesterone receptor (PR)-positive breast cancer cells and in PR-negative normal cells. In MCF10A normal epithelial PR-
negative cells, progesterone-treatment and irradiation triggered cancer and stemness-associated microRNA regulations
(such as the downregulation of miR-22 and miR-29c expression), which resulted in increased proportions of radiation-
resistant tumor-initiating CSCs.
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Introduction
Worldwide, breast cancer represents 16% of all cancer
incidence among women and 13.7% of cancer deaths [1]. It was
shown that women who had received medium or high-dose
ionizing radiation to the chest (for example, as treatments for other
cancers, such as Hodgkin’s lymphoma) have a relative risk of
breast cancer between 2.1 and 4.0 [2]. By age 45 years, up to 20%
of women exposed to chest ionizing radiation for a pediatric
malignancy are diagnosed with breast cancer [3]. New data are
coming to light indicating that even low dose exposures (such as
diagnostic chest X-rays for tuberculosis or pneumonia) might raise
this risk [4]. Sex steroid hormones such as estrogen and
progesterone play a crucial role in the development and
homeostasis of the mammary gland, by regulating proliferation,
differentiation and apoptosis. Evidence from the last few decades
supports the idea that accumulated exposure to steroid hormones
(for example in post-menopausal women under hormonal
replacement therapy) is also a risk factor for breast cancer [5].
The interplay between steroid hormones and radiation-induced
risks has been described. For example, we have shown that
progesterone protects cultured mammary cells against radiation-
induced apoptosis and increases the number of proliferating cells
containing chromosomal damage [6]. However, our knowledge of
hormonal action in the irradiated breast is far for complete and
new discoveries are challenging some established paradigms.
Recently, a lot of attention has be given to a small population of
malignant cells thought to be responsible for tumor maintenance
and initiation of relapse. These cancer stem cells (CSCs) possess
the ability to self-renew (thus to form tumors) and to cause the
different lineage of cancer cells comprising a tumor [7]. Breast
CSCs were first observed by Al Hajj et al., who described the
existence of a subpopulation of CD44+CD24lowESA+lineage2
human breast cancer cells capable of initiating tumors in immune-
deficient NOD/SCID mice [8]. CSC populations have been
defined using several combinations of cell-surface markers, such as
CD44+CD242 [9,10], or by measuring cellular activities, such as
the expression of aldehyde dehydrogenase (ALDH) [11]. In a
recent study, it was shown that breast cancer cell lines contain
breast CSCs [12]. CSCs may arise from normal stem cells, or from
a differentiated progenitor, which acquired self-renewal abilities.
CSCs are thought to be radio-resistant [13,14] and have a distinct
molecular signature [12].
Both estrogens and progesterone have strong proliferative
effects on stem/progenitor cells. Several studies have shown that
progesterone regulates genes (Notch pathway genes DLL-1, DLL-
3, IL6, PRSS2, Interleukins IL6 and IL8 and others) potentially
involved in stem cell regulation [15]. Estrogen was recently shown
to stimulate CSC expansion through FGF signaling [16]. It was
also shown that radiation exposure or steroid hormones can
contribute to the initiation of epithelial-to-mesenchymal transition
(EMT) and the expansion of CSCs subpopulation [17]. However,
to date, the potential involvement of steroid hormones in the
radiation-triggered EMT is unknown.
New developments also bring new light into the molecular
mechanisms of hormonal action. In the normal human breast,
estrogen and progesterone receptors (ER and PR, respectively) are
expressed in only 15 to 30% of the luminal epithelial cells and not in
other cell types [18]. It is thought that receptor-containing cells
secrete paracrine factors that influence the proliferation and activity
of nearby receptor-negative cells [19]. Recent investigations have
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shown that cultured MCF10A normal epithelial cells that do not
express PR are nonetheless responsive to progesterone [20].
Furthermore, CSCs can be generated during the transformation
of MCF10A cells [21].
In this study, we tested the hypothesis that steroid hormones
(estrogen and progesterone) could influence the radiosensitivity of
human breast cells and the potential breast cancer risks by
stimulating the expansion of breast CSCs. We also evaluated the
ability of progesterone to generate CSCs in irradiated PR2
MCF10A cells and we measured progesterone-associated miRNA
regulations.
Materials and Methods
Cell Cultures
T-47D and MCF10A cell lines were provided by Dr Daino
(NIRS), MCF7 cell line was provided by Dr Mori (NIRS). T-47D
and MCF7 breast cancer cell lines were maintained as previously
[6]in Dulbecco’s modified Eagle medium (DMEM) with 4.5 g/L
glucose, 0.11 g/L sodium pyruvate, glutamate (GlutaMAX 1t) and
pyridoxine, supplemented with 5% fetal calf serum, penicillin and
streptomycin. Non-tumorigenic MCF10A breast epithelial cells
[22] were maintained in DMEM/F12 supplemented with 5%
horse serum, 20 ng/mL epidermal growth factor (EGF), 10 mg/
mL insulin, 100 mg/mL hydrocortisone and 10 ng/mL cholera
toxin. Cultures were grown in 5% CO2 at 95% humidity.
Irradiation and Hormonal Treatment
Cells were irradiated in serum-free medium 72 hours after
plating, using an X-ray generator (ISOVOLT Titan-320, General
Electric, Fairfield, CT, USA). Irradiation dose was 10 Gy at a
dose-rate of 0.9 Gy/min. Starting one day after plating, natural
progesterone and estrogen diluted in ethanol (10 mM) were added
to the culture medium once a day until cell collection at a final
concentration of 10 nM. MCF10A cells were also cotreated with
10 mM mifepristone (diluted in ethanol) or 10 mM PD173074
inhibitor (diluted in DMSO).
Proliferation and Survival
At least 200 cells per sample (in three separate experiments)
were scored for proliferation and survival analysis. Discrimination
between viable and dead cells (including dead cells in the
supernatant) was performed after trypan blue staining.
Measurement of ROS Levels
Intracellular levels of ROS in MCF10A cells were measured
using 5-(and-6)-chloromethyl-29,79-dichlorodihydrofluorescein di-
acetate, acetyl ester (CM-H2DCFDA, Molecular Probes, Eugene,
OR, USA). Cells were plated in 12-well plates and loaded with
pre-warmed PBS containing 10 mM CM-H2DCFDA. Next, cells
were returned to pre-warmed medium and incubated for 40
minutes with 10 nM progesterone and mifepristone. Then,
fluorescence intensities were measured using a SpectraMax M5
microplate reader (Molecular Devices, Sunnyvale, CA, USA)
(excitation at 493 nm, emission at 520 nm). Unstained cells were
used as negative control. Cells treated with 100 mM H2O2 were
used as positive control.
Separation of ALDEFLUOR-positive Cells by Flow
Cytometry
ALDH activity in the cells was evaluated by flow cytometry
using the ALDEFLUOR kit (Stemcell technologies, Vancouver,
BC, Canada). Cells expressing with low and high levels of ALDH
enzymatic activity (respectively ALDH2 and ALDH+ cells) were
identified and sorted with a FACSAria cell sorter (BD Biosciences,
Franklin Lakes, NJ, USA). As a negative control, cells were treated
with diethylaminobenzaldehyde, a specific ALDH inhibitor.
Anchorage-independent Culture
Sorted ALDH2 and ALDH+ cells were resuspended in
complete mammosphere cell culture medium (MammoCult;
Stemcell Technologies) supplemented with Mammocult prolifer-
ation supplement, hydrocortisone and heparin. Then they were
seeded in ultra-low adherent plates (Corning, Corning, NY, USA)
at densities of 5,000 to 40,000 cells per well and grown for 7 days.
Spheres larger than 60 mm in size were counted.
Total RNA Extraction
Total RNA containing microRNAs was extracted using TRIzol
and a protocol slightly modified from the manufacturer’s
instructions. During the precipitation phase, 0.8 mL of isopropa-
nol was added per 1 mL of TRIzol reagent, then the samples were
incubated for 2–3 min at room temperature. RNA was washed
with 70% ethanol. Quantity and quality of RNA samples was
evaluated using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Montchanin, DE, USA).
Real-time PCR-based miRNA Expression Profiling
250 ng RNA per sample was reverse transcribed using the RT2
first strand kit (SABiosciences, Frederick, MD, USA), then real-
time PCR reactions were performed in triplicate with an Applied
Biosystems 7300 Real-Time PCR system (Life Technologies,
Carlsbad, CA, USA), using the RT2 SYBR Green PCR Master
Mix (SABiosciences) on 96-well Human Breast Cancer miRNA
PCR Arrays (MIHS-109Z, SABiosciences), which allowed to
analyze the differential expression of 84 miRNAs known or
predicted to be associated with breast cancer, according to the
manufacturer’s instructions.
microRNA Expression Data Analysis
Data analysis was performed using the web-based miRNA PCR
Data Analysis Software from SABiosciences (http://
pcrdataanalysis.sabiosciences.com/mirna/arrayanalysis.php). The
DDCt2 method was used the relative microRNA expression levels
in each group. For each microRNA, fold changes (compared to
levels in control cells) were calculated, then expressed as fold
regulations (for fold changes ,1, fold regulations were equal to
21/fold change; for fold changes $1, fold regulations were equal
to fold change).
We identified the molecular pathways potentially altered by
deregulated microRNAs (fold change .4, p,0.05) using the
DIANA-mirPath software combined with the DIANA-microT
v3.0 prediction software [23], which provided a list of enriched
KEGG pathways, with associated p-values.
Results
Steroid Hormones Modulate Radiation-induced Cell
Death
We first measured proliferation and viability three days after X-
ray irradiation in cultured steroid receptor-positive and receptor-
negative cells exposed to progesterone and estrogens treatment
(Fig. 1). In order to assess the role of PR in the observed
progesterone-induced effects, cells were also treated with mifep-
ristone, a PR antagonist. Because estrogen effects were shown to
Steroid Hormones and Breast Cancer Stem Cells
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be mediated through FGF signaling, cells were treated as well with
PD173074, an FGF-receptor inhibitor.
Exposure to 10 Gy X-rays inhibited proliferation in T47D,
MCF7 and MCF10A cells (Fig. 1A, C, E). Exposure to
progesterone inhibited the proliferation of non-irradiated T47D
and MCF7 cells, but did not modulate the proliferation of
MCF10A cells. Progesterone stimulated the proliferation of
irradiated T47D, MCF7 and MCF10A cells. Progesterone effects
on the proliferation of T47D and MCF7 cells were inhibited by
mifepristone, suggesting that progesterone mediated its effects
through PR. Mifepristone did not have any effect on the
proliferation of MCF10A non-irradiated and irradiated cells,
indicating that progesterone effect on MCF10A proliferation did
not rely on PR.
The percentage of dead cells was not significantly modulated by
hormonal treatment (it did not exceed 2% in each cell line), but it
increased significantly after exposure to 10 Gy X-rays (Fig. 1B, D,
F). In accordance with our earlier results [6], progesterone
treatment significantly reduced the radiation-induced cell death in
T47D cells. Interestingly, a similar protective effect of progester-
one was also observed in MCF10A cells. Co-treatment with
mifepristone counteracted the protective effect of progesterone in
T47D but not in MCF10A cells, confirming that this hormonal
protective effect did not rely on PR in MCF10A cells. Even though
progesterone did not significantly decrease the percentage of dead
MCF7 cells, we observed a significant increase of dead MCF7 cells
after co-treatment with mifepristone, which might suggest that
progesterone might also slightly protect MCF7 cells against
radiation-induced cell death through PR.
On the contrary, estrogen treatment elicited a weak protective
effect only in T47D cells (about 15% dead cells), as the percentages
of dead cells were non significantly different in treated and non-
treated irradiated MCF7 and MCF10A cells (Fig. 1B, D and F).
Co-treatment of irradiated MCF7 cells with PD173074 inhibitor
drew inconclusive results, because the differences were not
significant.
In summary, progesterone and oestrogen partly counteracted
the radiation-induced proliferation inhibition. Progesterone pro-
tected against radiation-induced cell death. In PR2 MCF10A
cells, progesterone effects were independent of PR expression.
Ionizing Radiation and Steroid Hormones Increase the
Proportion of ALDH+ Cells
We measured the proportion of cancer stem cells (CSCs) by flow
cytometry, using activity of aldehyde dehydrogenase (ALDH) as a
marker with the ALDEFLUOR kit (Fig. 2). About 1% of untreated
T47D cells, 0.5% of untreated MCF7 cells and 0.2% of untreated
MCF10A cells were ALDH+. On the contrary, the proportion of
ALDH+ T47D cells was significantly increased after 10 Gy
irradiation (2.2%) and after hormonal treatment with progesterone
(3.4%) and estrogen (3.6%). Progesterone treatment of irradiated
T47D cells resulted in a similar increase in the proportion of
ALDH+ cells (3.6%), but no additive effect of irradiation and
progesterone treatment was observed. The proportion of ALDH+
cells after estrogen treatment of irradiated T47D cells was slightly
higher than in irradiated non-treated cells, but slightly lower than
in treated non-irradiated cells (2.7%, non-significant differences).
In the MCF10A cell line, no increase in the proportion of ALDH+
cells was observed after hormonal treatment or after 10 Gy
Figure 1. Proliferation and viability of MCF7, T47D and MCF10A cells after irradiation and steroid hormone treatment. Proliferation
of T47D (A), MCF7 (C) and MCF10A (E) cells and the number of dead T47D cells (B), MCF7 (D) and MCF10A (F) cells were measured three days after
irradiation. Cells were seeded at a density of 105 cells/mL three days before irradiation. Hormonal treatment was performed two days before
irradiation and every day afterwards. Pg: progesterone, Mif: mifespristone, E2: estrogen, Inh: PD173074. Results are representative of at least three
independent experiments. Error bars represent standard deviation. Asterisks denote significant differences (t-test, *p,0.05, **p,0.01).
doi:10.1371/journal.pone.0077124.g001
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radiation exposure alone (less than 0.5%). A significant increase
was observed only when MCF10A cells were exposed both to
progesterone treatment and radiation exposure (4.0%). Cotreat-
ment with mifepristone did not significantly reduce the proportion
of ALDH+ cells (2.7%). Significant increases in the proportion of
CD44+/CD24- cells were also observed after progesterone
treatment and radiation exposure (Figure S1). These results
suggested that ionizing radiation and/or steroid hormone treat-
ment could stimulate the expansion of CSCs. In irradiated
MCF10A cells, progesterone action was independent of PR
expression.
ALDH+ Cells Show Increased Tumorphere-forming
Abilities and Radioresistance
In order to confirm whether the population of ALDH+ cells had
indeed tumor-initiating ability, we measured the capacity of
ALDH+ cells to grow ‘‘tumorspheres’’ (or ‘‘mammospheres’’) in
anchorage-independent conditions [12]. In each cell line, ALDH+
cells showed increased tumorsphere-forming capacity, compared
with ALDH2 cells, as observed in Fig. 3 (the numbers of
mammospheres formed for 1000 cells plated were: T47D: 2.7
ALDH2, 12 ALDH+/MCF7:3.4 ALDH2, 15.8 ALDH+/
MCF10A: 1.5 ALDH2, 17.7 ALDH+).
Figure 2. Proportion of CSCs after irradiation and steroid hormone treatment. The percentages of ALDH+ T47D (A), MCF7 (B) and MCF10A
(C) cells were evaluated by flow cytometry three days after irradiation. Hormonal treatment was performed two days before irradiation and every day
afterwards. Pg: progesterone, Mif: mifespristone, E2: estrogen, Inh: PD173074. Results are representative of at least three independent experiments.
Error bars represent standard deviation. Asterisks denote significant differences (t-test, *p,0.05, **p,0.01).
doi:10.1371/journal.pone.0077124.g002
Figure 3. Mammosphere-forming ability of ALDH2 cells and
ALDH+ CSCs. Sorted ALDH2 and ALDH+ T47D, MCF7 and MCF10A
cells were plated in ultra-low adherence plates and the number of
mammospheres formed after 7 days was counted. Error bars represent
standard deviation. Results are representative of three independent
experiments. Error bars represent standard deviation. Asterisks denote
significant differences (t-test, *p,0.05, **p,0.01).
doi:10.1371/journal.pone.0077124.g003
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Reproductive clonogenic viability of ALDH2 and ALDH+ cells
was evaluated by the colony forming assay (Fig. 4). In each cell
line, ALDH+ cells showed increased radioresistance compared to
ALDH2 cells. The dose that gave 50% mean clonogenic survival
was higher in ALDH+ (T47D: 2.5 Gy/MCF7:2.5 Gy/MCF10A:
2.3 Gy) than in ALDH2 cells (T47D: 1.9 Gy/MCF7:2 Gy/
MCF10A: 2.1 Gy).
Overall these results suggested that the ALDH+ cell population
was enriched in radioresistant CSCs.
Progesterone Treatment in MCF10A Cells Results in
Increased ROS Levels
Because the observed progesterone effects in MCF10A cells
were independent of PR expression, we decided to assess its
possible mechanisms of action. In order to confirm recent reports
of non-genomic action of progesterone in MCF10A cells, we first
measured ROS levels after progesterone treatment in MCF10A
cells. 40 minutes after progesterone addition, ROS levels were
significantly higher than in control cells (Fig. 5). Co-treatment with
mifepristone did not decrease the ROS levels.
The Modulation of CSC Levels by Progesterone and
Radiation in MCF10A Cells Involves Cancer-associated
microRNA Regulations
In order to assess whether progesterone action in MCF10A cells
involved miRNA regulations, we measured using PCR arrays the
expression levels of 84 miRNAs known or predicted to be
regulated during breast cancer initiation or progression. miRNA
levels were profiled in (1) untreated control MCF10A cells, (2)
MCF10A cells exposed to progesterone treatment alone, (3)
ALDH2 cells and (4) ALDH+ cells after progesterone treatment
and irradiation. Fig. 6 shows a heatmap of microRNA expression
levels for each group. Fold changes compared to control group
were calculated and expressed as fold regulations. Comparative
microRNA expression levels are presented in Fig. 7. Some
significant microRNA regulations (fold change .4 or ,24,
p,0.05) are presented in Table 1. A functional analysis of the gene
targets of these microRNAs was performed using the DIANA-
miRPath software. An enrichment analysis of these gene targets
provided a list of cell functions and pathways (based on Kyoto
Enyclopedia of Genes and Genomes – KEGG – nomenclature)
likely to be affected or involved in each experimental group
(Table 2, p,0.01). Several of these KEGG pathways were related
to cellular interactions (ECM–receptor interaction, Focal adhesion,
Adherens junction), signaling pathways (MAPK signaling pathway, p53
signaling pathway, VEGF signaling pathway, Phosphatidylinositol signaling
system, TGF-beta signaling pathway) or other cancers. A similar
enrichment analysis was performed to compare target gene
functions in ALDH2 and ALDH+ cells (Table 3); these functions
were related to cell adherence (ECM –receptor interaction, Focal
adhesion, Adherens junction), signaling pathways (MAPK signaling
pathway, TGF-beta signaling pathway) and other cancers.
Discussion
In the light of increased breast cancer risks in women exposed to
ionizing radiation, it is crucial to better evaluate the various
additional risk factors that could further result in breast cancer.
There is strong evidence that steroid hormones influence breast
cancer risk, but the molecular mechanisms are poorly understood.
Figure 4. Dose-response curves for clonogenic survival of
ALDH2 cells and ALDH+ CSCs. Sorted ALDH2 (squares, continuous
lines) and ALDH+ (circles, dotted lines) T47D (A), MCF7 (B) and MCF10A
(C) cells were exposed to various doses of ionizing radiation. Lines
represented fitted curves according to linear quadratic regression.
Results are representative of at least three independent experiments.
Error bars represent standard deviation. Statistical significance of the
difference between dose-response curves (p,0.05) was performed
using one-way Analysis of Variance (one-way ANOVA) with Bonferroni
correction for pairwise group comparisons.
doi:10.1371/journal.pone.0077124.g004
Figure 5. ROS levels in MCF10A cells. ROS levels were measured 40
minutes after treatment with progesterone or co-treatment with
progesterone and mifepristone. As a positive control, MCF10A were
treated with H2O2. Results are representative of at least three
independent experiments. Error bars represent standard deviation.
Asterisks denote significant differences (t-test, **p,0.01).
doi:10.1371/journal.pone.0077124.g005
Steroid Hormones and Breast Cancer Stem Cells
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We, and others, had previously shown that steroid hormones can
influence radiosensitivity in breast cells. In this study, we assessed
in vitro the potential role of breast cancer stem cells (CSCs) in the
modulation of radiosensitivity by steroid hormones, and we
observed for the first time that progesterone treatment of
irradiated PR- cells results in increased numbers of CSCs.
A protective effect of progesterone (in the three cell lines) and
estrogen (in MCF7 cells only) against radiation-induced cell death
was observed, confirming earlier reports [24–26]. Unsurprisingly,
the protective effect of progesterone was dependent on PR in
T47D and MCF7 cells, but not in MCF10A cells. This protective
effect was a direct effect of progesterone on the induction of
radiation-induced apoptosis, which might result from the modu-
lation of pro- or anti-apoptotic genes, such as HRK [6], or from
the regulation of cell signaling pathways involved in apoptosis
(PI3/Akt…). In MCF10A cells, it was shown that progesterone
treatment inhibited apoptosis induced by activation of the FasL
pathway, as seen by decreased caspase 3 and caspase 7 levels [20].
The apoptosis-regulating properties of estrogen are also well
known: depending on the experimental model, estrogen action has
been described as anti-apoptotic or pro-apoptotic [27]; in T47D
and MCF7 cells, estrogen regulates the expression of anti-
apoptotic proteins such as bcl-2 [28]. However, only a weak
protective effect of estrogen was observed in our study.
Compared to their non-CSC counterparts, CSCs in each cell
line showed increased radioresistance, in accordance with
published data. For example, in MCF7 and MDA-MB-231 cell
lines, CSCs (CD44+/CD242) were shown to be more radioresis-
tant than non-CSCs, based on clonogenic survival, ROS levels
and phosphorylation of cH2AX [29]. Radioresistance of progen-
itors cells was also shown in several other models. For example,
mouse mammary stem cells (defined as a lin2CD24+CD29+ side
population) exhibited resistance to radiation [30]. Radiation
exposure resulted in the expansion of human (MCF7) and murine
side population progenitors [30].
We measured the proportion of CSCs in the three cell lines in
order to assess the role of CSCs in this hormonal modulation of
radiosensitivity. Neither hormonal treatment nor irradiation
modulated the proportion of ALDH+ MCF7 cells. We did not
observe any increase in the proportion of ALDH+ MCF7 cells
after estrogen treatment, contrary to a recent report showing an
expansion of CD44+/CD242 cells [16]. However, estrogen was
added at a final concentration of 10 nM in our study and 1 nM in
that other study; a possible dose effect cannot be ruled out. On the
contrary, progesterone and estrogen stimulated the expansion of
the CSC population in irradiated and non-irradiated luminal
breast cancer T47D cells, which could result either from a
stimulation of CSC proliferation or from the reprogramming of
non-CSCs which would acquire a stem-like phenotype. In the
normal mammary gland, stem/progenitor cells do not express
progesterone receptor (PR) nor estrogen receptor (ER), but receive
hormonal paracrine signaling from luminal PR+/ER+ cells [31].
Similarly, in cultured breast cancer cells, the non-CSC compart-
ment might stimulate the expansion of CSCs through paracrine
signaling. Indeed, it has been shown that the secretion of FGF9 in
Figure 6. Heatmap of microRNA expression in MCF10A cells.
Each column represents one experimental group and each row
represents one microRNA. microRNAs were arranged by unsupervised
hierarchical clustering. Green and red indicate down- and upregulation,
respectively, relative to the overall mean expression for each microRNA.
The four experimental groups were: 1) non-irradiated cells (control); 2)
cells exposed to progesterone treatment alone (Pg); 3) ALDH2 cells and
4) ALDH+ cells after irradiation and progesterone treatment.
doi:10.1371/journal.pone.0077124.g006
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estrogen-treated MCF7 cells leads to the increase of the CSC
population [16]. On the other hand, in T47D cells, progesterone
was shown to transform PR+/ER+ cells into PR2/ER2 cells
expressing a myoepithelial CK5+ phenotype (associated with
stemness in the human breast), through an autocrine mechanism
[15,32], suggesting that progesterone might contribute to the
transformation of cells into CSCs.
It is generally accepted that in the normal breast, steroid
hormones target only a small proportion of hormone receptor-
expressing cells, which communicate with other cells through
paracrine interactions [7]. However, some evidence has emerged
showing that PR-negative MCF10A cells are also directly
responsive to progesterone [20,33,34], suggesting that progester-
one action in the normal breast might also target PR-negative
epithelial cells. For this reason, we investigated whether proges-
terone could influence the proportion of CSCs in irradiated
MCF10A cells. Untreated MCF10A containted less than 0.5%
CSCs [12]. Progesterone treatment of non-irradiated MCF10A
did not trigger any effect at any of the considered endpoints
(proliferation, cell death, proportion of CSCs), but the fact that we
observed hormonal effects (protection against radiation-induced
cell death and increased numbers of CSCs) in irradiated cells
suggested that progesterone nonetheless has direct action on
MCF10A cells.
To date, our understanding of non PR-related progesterone
action remains partial. Several controversial novel candidate
receptors mediating genomic and non-genomic progesterone
effects were identified during the last decade. A G-protein coupled
receptor, called membrane (m)-PR, was first characterized in fish
ovaries [35]. The three human mPR isoforms (mPRa, mPRb and
mPRx) present different tissue distributions and expression
patterns through the reproductive cycle. mPRa expression was
observed in MCF7 and SK-BR-3 cells, and its expression was
higher in breast tumor biopsies than in normal tissue from the
same breast [36]. However, the role of mPRs in progesterone
signaling is debated by several studies questioning its localization
or even its ability to bind progesterone [37,38]. Progesterone
membrane receptor component 1 (PGMRC1) is another mem-
brane progesterone receptor [39], whose expression was observed
in various models including breast cancer cells.
Figure 7. Comparative microRNA expression levels in MCF10A cells. Each scatter plot shows microRNA expression levels (logarithmic scale)
for two experimental groups: cells exposed to progesterone treatment alone (Pg) vs non-irradiated cells (Control) (A), ALDH2 cells (after irradiation
and progesterone treatment) vs Control (B), ALDH+ cells (after irradiation and progesterone treatment) vs Control (C), ALDH+ cells vs ALDH2 cells (D).
The outer diagonal lines indicate 4-fold differences in microRNA expression. Each microRNA is represented by a circle.
doi:10.1371/journal.pone.0077124.g007
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In MCF10A cells, non-genomic action of progesterone resulted
in increased mitochondrial activity (observed as increased mito-
chondrial potential) and subsequent inhibition of Fas-induced
apoptosis [20]. A strong correlation exists between mitochondrial
membrane potential and reactive oxygen species (ROS) levels
[40,41]. In accordance with these results, we observed a PR-
independent increase in ROS levels after progesterone treatment
of MCF10A cells.
In addition to non-genomic effects, our results indicated that
progesterone action in MCF10A cells involves genomic effects.
Several microRNAs were strongly down- (miR-22-3p, miR-29c-
3p) or upregulated (miR-328, miR-98-5p) by progesterone and
might contribute to the observed hormonal effects. miR-22 is a
tumor suppressor that induces cellular senescence (by targeting
CDK6, SIRT1 and Sp1) [42] and is frequently downregulated in
ER+ breast cancer [43]. miR-29c is downregulated in inflamma-
tory breast cancer [44] and its expression is associated with good
prognosis [45]. Another recent study has shown that progesterone
decreased miR-29 expression in breast cancer cells lines expressing
PR and ER (T47D and BT474), resulting in the upregulation of
Kru¨ppel-like factor 4 (KLF4), a transcription factor required for
the dedifferentiation into pluripotent stem cell phenotype and for
the maintenance of CSCs; as a consequence, the authors observed
an expansion of CK5+/CD44+ tumor-initiating cells [46].
Compared to control cells, both miR-22 and miR-29c were
downregulated not only after progesterone treatment, but also
after irradiation in ADLH2 and ALDH+ cells. miR-98, a Let-7
family member, was recently shown to inhibit Fas-mediated
apoptosis in Hela cells [47], in accordance with the anti-apoptotic
effect of progesterone. The precise role of miR-238 in human
cancer is not yet fully elucidated: while it was overexpressed in
patients with non-small cell lung cancer brain [48], loss of miR-
328 expression occurred in blast crisis chronic myelogenous
leukemia [49]. The involvement of miR-328 in breast cancer has
not been established to date. We performed a functional analysis of
the target genes for the microRNAs deregulated after progesterone
treatment and irradiation. The modulation of cell adhesion (ECM-
receptor interaction, Focal adhesion…) and the remodeling of actin
cytoskeleton are functions which might be important for epithelial-
to-mesenchymal transition (EMT) and cancer initiation [50].
Ionizing radiation was previously shown to predispose breast cells
to transforming growth factor beta (TGFb)-induced EMT [17],
independently of radiation dose or LET [51]. Overall the observed
microRNA regulations are consistent with cancer-related process-
es.
Control and progesterone-treated MCF10A populations con-
tained negligible amounts of CSCs. On the contrary, after
irradiation and progesterone treatment, the cell population
contained both non-CSCs and CSCs, whose microRNA expres-
sion patterns were different both from each other and from non-
irradiated cells (control and progesterone-treated cells). Using an
inducible breast oncogenesis model based on MCF10A cells,
Iliopoulos et al. have shown that CSCs and non-CSCs exist in a
dynamic equilibrium that can be influenced by an inflammatory
feedback loop involving NF-kB, Lin28, IL6, STAT3, PTEN,
CYLD and several microRNAs (let-7, miR-21, miR-181b-1) [21].
In our study, after irradiation and progesterone treatment, two let-
7 family microRNAs were significantly downregulated in ALDH+
cells, compared to ALDH2 cells (Table 1). The let-7 family
microRNAs (which includes 13 human homologues) were among
the first to be directly described as tumor suppressors, by
negatively regulating the expression of the Ras oncogene [52].
Loss of let-7 expression was observed in many human cancers and
is associated with poor survival [53] and stem cell phenotype [54].
Taken together, our results suggested that the increased
numbers of CSCs induced by steroid hormones might contribute
to the modulation of radiosensitivity by the hormone in T47D
breast cancer cells, but not in MCF10A cells. However, we report
for the first time that progesterone directly triggered microRNA
regulations and modulated the radiosensitivity of normal breast
epithelial cells lacking the expression of PR, suggesting that the
classical model of hormonal paracrine action in the normal breast
[55] may need to be completed. Furthermore, the combination of
progesterone treatment and radiation exposure was capable of
generating CSCs. The origin of CSCs is still a matter of ample
controversy: some have suggested that CSCs might result from
already malignant cells through a clonal evolution process [56].
Our results are consistent with the idea that progesterone and
radiation exposure might trigger or contribute to cancer initiation
events, resulting in the appearance of CSCs.
Although MCF10A possess some genetic abnormalities, they
are generally considered as a ‘‘normal’’ cell line, whose
morphogenesis on reconstituted basement membrane is similar
to what is observed with normal breast epithelial cells [57].
MCF10A cells express markers associated with a basal phenotype
[58], which can give rise to basal-type cancers. On that account,
MCF10A might be an appropriate model for evaluating breast
cancer risks and initiation. Therefore, we can hypothesize that the
combined effects of irradiation and progesterone on tumor-
initiating CSCs might contribute to additional cancer risk [59] in
the normal breast.
Additionally, increased numbers of CSCs were also observed in
PR+/ER+ T47D breast cancer cells after steroid hormone
treatment and irradiation. Convincing evidence suggest a link
between CSCs and metastasis in cancer models [60]. For example,
metastatis in inflammatory breast cancer is mediated by ALDH+
CSCs [61]. Similarly, human CSCs are involved in spontaneous
Table 1. Significant microRNA regulations in MCF10A cells.
miRNA
Fold
regulation p-value
Pg vs Control miR-22-3p 211.0 0.01
miR-29c-3p 23.5 0.03
miR-328 33.9 0.00
miR-98-5p 15.4 0.03
ALDH2 vs Control miR-19a-3p 24.7 0.01
miR-210 29.3 0.03
miR-29b-3p 210.0 0.03
Let-7e-5p 19.7 0.04
ALDH+ vs Control miR-128 25.7 0.03
miR-15b-5p 24.2 0.03
miR-17-5p 26.3 0.02
miR-195-5p 228.4 0.04
miR-19a-3p 28.0 0.00
miR-20b-5p 24.0 0.04
miR-22-3p 24.3 0.03
ALDH+ vs ALDH2 Let-7e-5p 219.6 0.04
Let-7f-5p 226.6 0.03
MicroRNA fold regulations were expressed relative to non-irradiated cells
(Control) or to ALDH2 cells. MicroRNAs regulated more than 4-fold (p,0.05)
were reported.
doi:10.1371/journal.pone.0077124.t001
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metastasis in mouse xenographt tumor models [62]. Therefore,
expansion of CSCs by progesterone in breast cancer might result
in additional metastasis risk.
In conclusion, our results suggest that progesterone might
influence radiation-induced breast cancer risk by generating
tumor-initiating breast cancer stem cells. In order to decrease
the potential risks of breast cancer resulting from chest ionizing
radiation exposure, it might be useful to take into account the
variability of progesterone levels during menstrual cycle and
between individuals. Our results also shed additional light on
elevated breast cancer risks in women treated with hormone
replacement therapy [63]. Further investigations are needed to
better understand the mechanisms involved in PR-independent
progesterone action in the normal breast and the generation of
CSCs after exposure to ionizing radiation, in particular in the low-
dose range.
Supporting Information
Figure S1 Proportion of CD44+/CD242 CSCs after
irradiation and steroid hormone treatment. The percent-
ages of CD44+/CD242 MCF10A cells were evaluated by flow
cytometry three days after irradiation, after labeling with
conjugated anti-human CD1332PE (phycoerythrin; Miltenyi
Biotec) and CD442FITC (Miltenyi Biotec). Hormonal treatment
was performed two days before irradiation and every day
afterwards. Pg: progesterone. Results are representative of three
independent experiments. Error bars represent standard deviation.
Asterisks denote significant differences (t-test, *p,0.05).
(TIFF)
Table 2. Functional analysis of the genes targeted by microRNA regulations.
Progesterone ALDH2 ALDH+
KEGG pathways
No of
genes KEGG pathways
No of
genes KEGG pathways
No of
genes
ECM-receptor interaction 26 Focal adhesion 19 Axon guidance 10
Focal adhesion 45 ECM-receptor interaction 12 Renal cell carcinoma 7
MAPK signaling pathway 49 Cell Communication 12 TGF-beta signaling pathway 8
p53 signaling pathway 18 mTOR signaling pathway 7 Pancreatic cancer 7
Glioma 17 Small cell lung cancer 7 Chronic myeloid leukemia 7
Oxidative phosphorylation 1 Prostate cancer 7 Bladder cancer 5
Amyotrophic lateral sclerosis 7 Melanoma 6 Wnt signaling pathway 10
Melanoma 17 Glioma 5 p53 signaling pathway 6
Adherens junction 17 VEGF signaling pathway 5 Prostate cancer 7
Glycerophospholipid metabolism 16 Endometrial cancer 4 Focal adhesion 11
Small cell lung cancer 19 T cell receptor signaling pathway 5 MAPK signaling pathway 13
Regulation of actin cytoskeleton 37 B cell receptor signaling pathway 4 GnRH signaling pathway 7
Glycan structures - biosynthesis 1 24 Renal cell carcinoma 4 Colorectal cancer 6
Ribosome 1 Type II diabetes mellitus 3
T cell receptor signaling pathway 19 C5-Branched dibasic acid metabolism 1
Colorectal cancer 18 Phosphatidylinositol signaling system 4
Pancreatic cancer 4
Apoptosis 4
Heparan sulfate biosynthesis 2
Insulin signaling pathway 5
Non-small cell lung cancer 3
Acute myeloid leukemia 3
Analysis of the gene targeted by each significantly modulated microRNA in each experimental group (relative to control) revealed several significantly enriched KEGG
pathways (p,0.01). KEGG pathway names and the number of associated target genes are reported in this table.
doi:10.1371/journal.pone.0077124.t002
Table 3. Functional analysis of the genes targeted by
microRNA regulations in CSCs.
ALDH+ vs ALDH2 No of genes
TGF-beta signaling pathway 9
MAPK signaling pathway 16
Colorectal cancer 8
Adherens junction 7
Type II diabetes mellitus 5
Pancreatic cancer 6
Chronic myeloid leukemia 6
ECM-receptor interaction 6
Focal adhesion 10
Analysis of the gene targeted by each significantly modulated microRNA in
ALDH+ cells, relative to ALDH2 cells, revealed several significantly enriched
KEGG pathways (p,0.01). KEGG pathway names and the number of associated
target genes are reported in this table.
doi:10.1371/journal.pone.0077124.t003
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Table S1 microRNA expression levels in MCF10A cells,
compared to control. For each experimental group (cells
exposed to progesterone treatment alone, ALDH2 cells and
ALDH+ cells after irradiation and progesterone treatment), fold-
changes (FCs) of miRNA expression were measured as compared
to non-irradiated and non-treated control cells. If the expression
ratios were .1, then FCs were equal to expression ratios. If the
expression ratios were ,1, then FCs were equal to the opposite of
expression ratios.
(PDF)
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